416 related articles for article (PubMed ID: 25924765)
41. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A.
Kyne L; Warny M; Qamar A; Kelly CP
N Engl J Med; 2000 Feb; 342(6):390-7. PubMed ID: 10666429
[TBL] [Abstract][Full Text] [Related]
42. Best strategies in recurrent or persistent Clostridium difficile infection.
Cocanour CS
Surg Infect (Larchmt); 2011 Jun; 12(3):235-9. PubMed ID: 21767157
[TBL] [Abstract][Full Text] [Related]
43. Development of a new serological assay for the diagnosis of Clostridium difficile infections with prognostic value.
von Bechtolsheim F; Varga A; Szereday L; Polgar B; Balassa T; Kocsis B; Peterfi Z; Miko E
J Microbiol Methods; 2019 Dec; 167():105777. PubMed ID: 31733265
[TBL] [Abstract][Full Text] [Related]
44. Clostridium difficile and the disease it causes.
Norén T
Methods Mol Biol; 2010; 646():9-35. PubMed ID: 20597000
[TBL] [Abstract][Full Text] [Related]
45. Actoxumab + bezlotoxumab combination: what promise for Clostridium difficile treatment?
Posteraro B; Pea F; Masucci L; Posteraro P; Sanguinetti M
Expert Opin Biol Ther; 2018 Apr; 18(4):469-476. PubMed ID: 29534621
[TBL] [Abstract][Full Text] [Related]
46. Circulating antibody and memory B-Cell responses to C. difficile toxins A and B in patients with C. difficile-associated diarrhoea, inflammatory bowel disease and cystic fibrosis.
Monaghan TM; Robins A; Knox A; Sewell HF; Mahida YR
PLoS One; 2013; 8(9):e74452. PubMed ID: 24058568
[TBL] [Abstract][Full Text] [Related]
47. Treatment and Prevention of Recurrent Clostridium difficile Infection with Functionalized Bovine Antibody-Enriched Whey in a Hamster Primary Infection Model.
Heidebrecht HJ; Weiss WJ; Pulse M; Lange A; Gisch K; Kliem H; Mann S; Pfaffl MW; Kulozik U; von Eichel-Streiber C
Toxins (Basel); 2019 Feb; 11(2):. PubMed ID: 30736358
[TBL] [Abstract][Full Text] [Related]
48. Sensitive assays enable detection of serum IgG antibodies against Clostridium difficile toxin A and toxin B in healthy subjects and patients with Clostridium difficile infection.
Zhao X; Bender F; Shukla R; Kang JJ; Caro-Aguilar I; Laterza OF
Bioanalysis; 2016 Apr; 8(7):611-23. PubMed ID: 26964649
[TBL] [Abstract][Full Text] [Related]
49. Development of a Novel Vaccine Containing Binary Toxin for the Prevention of Clostridium difficile Disease with Enhanced Efficacy against NAP1 Strains.
Secore S; Wang S; Doughtry J; Xie J; Miezeiewski M; Rustandi RR; Horton M; Xoconostle R; Wang B; Lancaster C; Kristopeit A; Wang SC; Christanti S; Vitelli S; Gentile MP; Goerke A; Skinner J; Strable E; Thiriot DS; Bodmer JL; Heinrichs JH
PLoS One; 2017; 12(1):e0170640. PubMed ID: 28125650
[TBL] [Abstract][Full Text] [Related]
50. [Investigation of toxin genes of Clostridium difficile strains isolated from hospitalized patients with diarrhoea at Marmara University Hospital].
Deniz U; Ulger N; Aksu B; Karavuş M; Söyletir G
Mikrobiyol Bul; 2011 Jan; 45(1):1-10. PubMed ID: 21341153
[TBL] [Abstract][Full Text] [Related]
51. Characterization of six murine monoclonal antibodies specific for toxin B of Clostridium difficile.
Coughlin RT; Annunziato M; Roberson J; Marciani DJ
Hybridoma; 1994 Apr; 13(2):147-52. PubMed ID: 8050780
[TBL] [Abstract][Full Text] [Related]
52. Protective efficacy induced by recombinant Clostridium difficile toxin fragments.
Leuzzi R; Spencer J; Buckley A; Brettoni C; Martinelli M; Tulli L; Marchi S; Luzzi E; Irvine J; Candlish D; Veggi D; Pansegrau W; Fiaschi L; Savino S; Swennen E; Cakici O; Oviedo-Orta E; Giraldi M; Baudner B; D'Urzo N; Maione D; Soriani M; Rappuoli R; Pizza M; Douce GR; Scarselli M
Infect Immun; 2013 Aug; 81(8):2851-60. PubMed ID: 23716610
[TBL] [Abstract][Full Text] [Related]
53. Induction of antitoxin responses in Clostridium-difficile-infected patients compared to healthy blood donors.
von Eichel-Streiber A; Paik W; Knight K; Gisch K; Nadjafi K; Decker C; Bosnjak O; Cheknis A; Johnson S; von Eichel-Streiber C
Anaerobe; 2016 Oct; 41():91-103. PubMed ID: 27427464
[TBL] [Abstract][Full Text] [Related]
54. Fecal microbiota transplantation and emerging treatments for Clostridium difficile infection.
Gens KD; Elshaboury RH; Holt JS
J Pharm Pract; 2013 Oct; 26(5):498-505. PubMed ID: 23966282
[TBL] [Abstract][Full Text] [Related]
55. Bezlotoxumab: anti-toxin B monoclonal antibody to prevent recurrence of Clostridium difficile infection.
Villafuerte Gálvez JA; Kelly CP
Expert Rev Gastroenterol Hepatol; 2017 Jul; 11(7):611-622. PubMed ID: 28636484
[TBL] [Abstract][Full Text] [Related]
56. [Preparation and characterization of monoclonal antibody against Clostridium difficile toxin A].
Fu SW; Zhou DY; Lai ZS; Xue J
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2004 May; 20(3):376-8. PubMed ID: 15193243
[TBL] [Abstract][Full Text] [Related]
57. A chimeric toxin vaccine protects against primary and recurrent Clostridium difficile infection.
Wang H; Sun X; Zhang Y; Li S; Chen K; Shi L; Nie W; Kumar R; Tzipori S; Wang J; Savidge T; Feng H
Infect Immun; 2012 Aug; 80(8):2678-88. PubMed ID: 22615245
[TBL] [Abstract][Full Text] [Related]
58. Binary toxin-producing, large clostridial toxin-negative Clostridium difficile strains are enterotoxic but do not cause disease in hamsters.
Geric B; Carman RJ; Rupnik M; Genheimer CW; Sambol SP; Lyerly DM; Gerding DN; Johnson S
J Infect Dis; 2006 Apr; 193(8):1143-50. PubMed ID: 16544255
[TBL] [Abstract][Full Text] [Related]
59. Adenovirus-based vaccination against Clostridium difficile toxin A allows for rapid humoral immunity and complete protection from toxin A lethal challenge in mice.
Seregin SS; Aldhamen YA; Rastall DP; Godbehere S; Amalfitano A
Vaccine; 2012 Feb; 30(8):1492-501. PubMed ID: 22200503
[TBL] [Abstract][Full Text] [Related]
60. Emergence and control of fluoroquinolone-resistant, toxin A-negative, toxin B-positive Clostridium difficile.
Drudy D; Harnedy N; Fanning S; Hannan M; Kyne L
Infect Control Hosp Epidemiol; 2007 Aug; 28(8):932-40. PubMed ID: 17620240
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]